Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Phase 3 “ultraVIOLET Study” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
– ultraVIOLET Trial Evaluating Efficacy of Oteseconazole (VT-1161) Compared to Fluconazole
– Top-line Data Remains on Track for Late 2020
Durham, N.C. – December 2, 2020 – Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the last patient has completed her final visit in Mycovia’s last Phase 3 clinical trial of oteseconazole (VT-1161) in patients with recurrent vulvovaginal candidiasis (RVVC).